Company Comparison
Forty Seven vs 54gene
Side-by-side comparison of two portfolio companies — sector, funding stage, investors, valuation, and more.
| Metric | Forty Seven | 54gene |
|---|---|---|
| Sector | Biotech | Biotech |
| Headquarters | Menlo Park, California | Lagos, Nigeria |
| Founded | 2014 | 2019 |
| Status | Active | Active |
| Last Funding Stage | Series C | Series B |
| Total Funding | $320M | $45M |
| Valuation | — | — |
What They Build
Forty Seven
Biotechnology company developing cancer immunotherapies targeting the CD47 pathway to enhance immune system recognition of cancer cells.
54gene
African genomics research company advancing precision medicine through genetic research focused on African populations.
Key Investors
Forty Seven
Sector Overlap
Both Forty Seven and 54gene operate in Biotech.
Browse all Biotech companies →Websites
Sponsored
AArchstone
The operating system for private capital.
Archstone runs the back office for venture, PE, real estate, and credit funds — LP reporting, capital calls, portfolio tracking, and fund accounting, in one platform. Now in alpha.
LP portal & reportingCapital callsPortfolio tracking$297/moNo AUM fees
Now in alpha with select funds. 14-day trial available.